DTMT Network

Alkem Laboratories, Mumbai based Indian Pharmaceutical company, on September 28, 2021, launched Pulmocare, a division to enhance awareness, diagnosis and management for lung diseases like asthma, COPD, allergy, advanced lung diseases and lung infections through a wide range of products for lung care with an objective to bring drastic change in lung treatment accessibility in India by way of early diagnosis, better patient reach and signified health promotion.

While launching the division, Mr. Sandeep Singh, MD, Alkem Laboratories Limited, said, “Taking the stock of filling the massive gap of accessibility of lung care for the larger populace in India, we have decided to take a big leap to address the huge lung diseases burden in the country by launching a comprehensive lung care division – Pulmocare."

"With the Alkem launch of the Pulmocare division, we shall spread awareness about the disease amongst the patients and encourage them to use correct medication," he added.

Adding further, Mr. Sandeep asserted, “Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives. We have evolved as one of the most preferred partners for doctors in infection management, nutraceuticals, gastric-care and paediatric care.”

As per the Global Burden of Diseases data and other research study, of more than 9 crore patients suffering from lung diseases, only one crore has access to right management of lung care in India. It seems 90% of lung patients are deprived of access to lung care, which brings to the fore, the massive treatment accessibility gap.

The causes of high lung disease burden have been identified as underutilization of diagnostic tools like spirometry; insufficient patient awareness of the disease; and delayed patient healthcare reach. This results in enormous health loss leading to deaths and/ or disability-adjusted life-years (DALY’s).